<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Histologic scoring systems for chronic liver disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Histologic scoring systems for chronic liver disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Histologic scoring systems for chronic liver disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Maria Isabel Fiel, MD, FAASLD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sanjiv Chopra, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 09, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H23839870"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Histologic scoring systems for chronic liver disease are used to characterize and predict disease progression, to determine prognosis, to guide treatment strategies, and to provide standards in clinical trials. </p><p>This topic will review the major histologic scoring systems for chronic liver disease. The interpretation of liver biopsy specimens in general and methods to obtain liver biopsy specimens are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15756.html" rel="external">"Interpretation of nontargeted liver biopsy findings in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3587.html" rel="external">"Approach to liver biopsy"</a> and  <a class="medical medical_review" href="/z/d/html/3586.html" rel="external">"Transjugular liver biopsy"</a>.)</p><p class="headingAnchor" id="H60230083"><span class="h1">LIMITATIONS OF LIVER BIOPSY</span><span class="headingEndMark"> — </span>There are several limitations of liver biopsy for assessing liver disease, including: </p><p class="bulletIndent1"><span class="glyph">●</span>Variable quality of liver biopsy specimens – Specimens shorter than 2 cm in length may be difficult to interpret [<a href="#rid1">1</a>]. Larger caliber needles may yield better samples than fine needle biopsies [<a href="#rid2">2,3</a>]. As an example, small specimens may underestimate the degree of inflammatory activity and fibrosis in patients with viral hepatitis [<a href="#rid4">4</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sampling variability – The assessment of liver histology is usually based on a percutaneous biopsy that samples a very small portion (1/50,000<sup>th</sup>) of the liver [<a href="#rid5">5</a>]. Liver disease does not always affect the liver in a homogeneous pattern, leading to the possibility of sampling variability. The most common setting for sampling error is in a cirrhotic liver [<a href="#rid5">5</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subjective assessment – This may lead to inter- and intraobserver variability or error [<a href="#rid6">6-8</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fluctuating disease activity – Histologic changes obtained at a single point in time may not reflect overall disease activity, which may vary.</p><p></p><p class="headingAnchor" id="H23839876"><span class="h1">CHRONIC HEPATITIS</span><span class="headingEndMark"> — </span>There are several scoring systems used to assess chronic hepatitis [<a href="#rid9">9-14</a>]. These systems help to assess prognosis and guide clinical management [<a href="#rid15">15</a>]. The scoring systems typically include descriptions of both necroinflammatory activity and the degree of fibrosis. An important difference among the scoring systems is in the staging of fibrosis. Scoring systems that include more stages for describing fibrosis are better able to document small changes in fibrosis over time. The Knodell score assigns patients to one of four stages, the METAVIR score to one of five, and the Ishak score to one of six.</p><p>Early scoring systems recognized two major histologic patterns, "chronic persistent hepatitis" and "chronic aggressive hepatitis" [<a href="#rid16">16</a>]. These patterns were associated with mild and more aggressive histologic categories of liver disease, respectively. Many other scoring systems were subsequently developed. For example, commonly used systems include:</p><p class="bulletIndent1"><span class="glyph">●</span>The Knodell score/histology activity index</p><p class="bulletIndent1"><span class="glyph">●</span>The METAVIR score</p><p class="bulletIndent1"><span class="glyph">●</span>The Ishak score (modified Knodell score)</p><p></p><p>Other scoring systems include:</p><p class="bulletIndent1"><span class="glyph">●</span>The Scheuer system</p><p class="bulletIndent1"><span class="glyph">●</span>The Batts-Ludwig system</p><p class="bulletIndent1"><span class="glyph">●</span>Laennec staging system</p><p></p><p>Most of the scoring systems for chronic hepatitis focus on viral etiologies, particularly hepatitis C virus (HCV) and hepatitis B virus infection. The same histologic scoring systems are used for autoimmune hepatitis. In rare instances, autoimmune hepatitis may be difficult to distinguish from chronic HCV [<a href="#rid17">17</a>].</p><p>The advent of highly effective, direct-acting antiviral medications for HCV has led to fewer liver biopsies being performed in order to grade and stage HCV because patients are often treated with anti-HCV medications regardless of the stage of fibrosis. (See  <a class="medical medical_review" href="/z/d/html/15832.html" rel="external">"Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection", section on 'Minimal role of liver biopsy'</a>.)</p><p class="headingAnchor" id="H23839896"><span class="h2">Knodell score/histology activity index</span><span class="headingEndMark"> — </span>The Knodell score (also known as the histology activity index) is a composite score that is based on histologic assessment of periportal and/or bridging necrosis, intralobular degeneration and focal necrosis, portal inflammation, and fibrosis (<a class="graphic graphic_table graphicRef56831" href="/z/d/graphic/56831.html" rel="external">table 1</a> and <a class="graphic graphic_picture graphicRef97253 graphicRef97269 graphicRef98079 graphicRef97270 graphicRef97271" href="/z/d/graphic/97253.html" rel="external">picture 1A-E</a>). The score ranges from 0 to 22, with higher scores representing more advanced disease [<a href="#rid9">9</a>]. A decrease in the Knodell score corresponds with histologic improvement. </p><p>The Knodell score is frequently used in trials of treatments for chronic hepatitis, particularly HCV. The score is used to assure that baseline histologic features in treatment groups are equally matched and to assess histologic changes after therapy.</p><p>A limitation of the Knodell score is that it combines inflammation and fibrosis to arrive at one composite score, so it is relatively insensitive to changes in fibrosis. This is important because it is fibrosis, and not inflammation per se, that leads to many of the sequelae of chronic liver disease. In addition, patients may have the same Knodell score despite having markedly different degrees of fibrosis. </p><p>The Knodell score is also associated with high inter- and intraobserver variability. In a study of 10 pathologists using a cohort of 30 liver biopsy specimens from patients who had documented HCV infection, interobserver correlation for the three inflammatory components of the Knodell score was relatively poor (with kappa coefficients ranging from 0.25 to 0.46 [a perfect coefficient being 1.00]) [<a href="#rid10">10</a>]. The interobserver correlation for the overall score was also relatively poor, ranging from 0.48 to 0.57. Only the fibrosis score had good reliability, with a kappa coefficient of approximately 0.80. Similar results were found for intraobserver reliability.</p><p class="headingAnchor" id="H23839890"><span class="h2">METAVIR score</span><span class="headingEndMark"> — </span>The METAVIR score is a semiquantitative classification system that consists of an activity score and a fibrosis score (represented by a two letter and two number coding system) (<a class="graphic graphic_table graphicRef98097" href="/z/d/graphic/98097.html" rel="external">table 2</a> and <a class="graphic graphic_picture graphicRef97272 graphicRef97279 graphicRef97281 graphicRef97280" href="/z/d/graphic/97272.html" rel="external">picture 2A-D</a>) [<a href="#rid10">10,11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The activity score is graded according to the intensity of necroinflammatory lesions (A0 = no activity, A1 = mild activity, A2 = moderate activity, A3 = severe activity).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The fibrosis score is assessed on a five-point scale (F0 = no fibrosis, F1 = portal fibrosis without septa, F2 = few septa, F3 = numerous septa without cirrhosis, F4 = cirrhosis).</p><p></p><p>In contrast to the Knodell score, which was designed as a generic scoring system for chronic hepatitis, the METAVIR score was specifically designed and validated for patients with HCV [<a href="#rid10">10</a>]. The inter- and intraobserver reliability of the activity and fibrosis scores of the METAVIR system are similar to the Knodell score. A study found that the interobserver agreement of the METAVIR score depends highly upon the experience of the hepatopathologist [<a href="#rid6">6</a>]. Agreement was influenced more heavily by the interpreter's experience than by features of the specimen itself, such as its length. However, a separate study evaluating the fibrosis and activity scores in specimens of various lengths suggested that the length of the biopsy is also important [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H23839902"><span class="h2">Ishak score (modified Knodell score)</span><span class="headingEndMark"> — </span>The Ishak score is a modification of the Knodell score that includes six stages of fibrosis (<a class="graphic graphic_table graphicRef98101" href="/z/d/graphic/98101.html" rel="external">table 3</a> and <a class="graphic graphic_picture graphicRef97283 graphicRef97296 graphicRef97297 graphicRef97298 graphicRef97299 graphicRef97300 graphicRef97301" href="/z/d/graphic/97283.html" rel="external">picture 3A-G</a>) [<a href="#rid12">12</a>]. This permits documentation of small changes in fibrosis compared with the standard Knodell fibrosis score, which has only four stages. Like the METAVIR score, the grades for necroinflammation (<a class="graphic graphic_picture graphicRef97282" href="/z/d/graphic/97282.html" rel="external">picture 4</a>) are categorized separately from the stage of fibrosis (<a class="graphic graphic_table graphicRef98099" href="/z/d/graphic/98099.html" rel="external">table 4</a>).</p><p>This staging system has become widely used in clinical trials because of its ability to detect mild changes in fibrosis.</p><p class="headingAnchor" id="H23839909"><span class="h2">Scheuer system</span><span class="headingEndMark"> — </span>The Scheuer system is a simple scoring system that separates necroinflammation from fibrosis [<a href="#rid13">13</a>]. Histologic findings of portal inflammation, interface hepatitis, and lobular inflammation are each assigned a score of 0 to 4 (<a class="graphic graphic_table graphicRef98102" href="/z/d/graphic/98102.html" rel="external">table 5</a>). A separate score (0 to 4) is assigned to the stage of fibrosis (<a class="graphic graphic_picture graphicRef97302 graphicRef97303 graphicRef97304 graphicRef97305" href="/z/d/graphic/97302.html" rel="external">picture 5A-D</a>).</p><p class="headingAnchor" id="H23841513"><span class="h2">Batts-Ludwig system (modified Scheuer system)</span><span class="headingEndMark"> — </span>This system is also known as the modified Scheuer system [<a href="#rid14">14</a>]. In the original description, diagrams of the different grades and stages of chronic hepatitis were depicted. Either a semiquantitative numeric value or a descriptive term can be used, depending on local preferences (<a class="graphic graphic_table graphicRef98103" href="/z/d/graphic/98103.html" rel="external">table 6</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Necroinflammatory activity (grade) is based on lymphocytic piecemeal necrosis (interface hepatitis) and lobular necroinflammatory activity (<a class="graphic graphic_picture graphicRef97370 graphicRef97371 graphicRef97373 graphicRef97374 graphicRef97375" href="/z/d/graphic/97370.html" rel="external">picture 6A-E</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The stage refers to the degree of fibrosis (<a class="graphic graphic_picture graphicRef97376" href="/z/d/graphic/97376.html" rel="external">picture 7</a>). </p><p></p><p>This grading system is applicable to both chronic viral hepatitis (<a class="graphic graphic_picture graphicRef97377" href="/z/d/graphic/97377.html" rel="external">picture 8</a>) and autoimmune hepatitis. This system is more useful for assessing an individual patient's liver biopsy for clinical care than it is for therapeutic trials.</p><p class="headingAnchor" id="H3368240759"><span class="h2">Scoring systems for cirrhosis</span><span class="headingEndMark"> — </span>More advanced stages of fibrosis, specifically cirrhosis, are not captured by the traditional staging systems described above. Two classifications, the Laennec staging system and the Beijing classification, have been proposed to address this issue [<a href="#rid18">18,19</a>]. </p><p class="headingAnchor" id="H23841551"><span class="h3">Laennec staging system</span><span class="headingEndMark"> — </span>The Laennec staging system is a modification of the METAVIR F4 (cirrhosis) fibrosis category and was developed based on the observation that cirrhosis may have different degrees of severity that influence the disease behavior and prognosis [<a href="#rid19">19</a>]. (See <a class="local">'METAVIR score'</a> above.)</p><p>The system subdivides F4 cirrhosis into three categories based on the width and number of fibrous septa, as well as the size of the nodules, with more emphasis given to micronodules (<a class="graphic graphic_picture graphicRef97379 graphicRef97380 graphicRef97381" href="/z/d/graphic/97379.html" rel="external">picture 9A-C</a> and <a class="graphic graphic_table graphicRef98104" href="/z/d/graphic/98104.html" rel="external">table 7</a>). </p><p>A positive correlation between the Laennec stage and hepatic venous pressure gradient was demonstrated by one study [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/90896.html" rel="external">"Portal hypertension in adults", section on 'Hepatic venous pressure gradient'</a>.)</p><p>Additional studies have shown that Laennec cirrhosis stage has prognostic value. For example, more severe cirrhosis has been associated with higher risk for a liver-related event (eg, decompensation, hepatocellular carcinoma [HCC]) or a worse outcome after surgical resection for HCC compared with less severe cirrhosis [<a href="#rid21">21,22</a>]. </p><p class="headingAnchor" id="H789254389"><span class="h3">Beijing classification</span><span class="headingEndMark"> — </span>The Beijing system subclassifies<strong> </strong>cirrhosis into three categories: predominantly progressive, indeterminate, or predominantly regressive (the P-I-R score) [<a href="#rid18">18,23</a>].The progressive category (P score) shows broad fibrous septa while the regressive category (R score) shows thin septa with foci of disintegration. The indeterminate category (I score) is a balance of regression and progression. This classification is particularly useful for patients with chronic viral hepatitis because it facilitates comparing the degree of cirrhosis before and after antiviral therapy (<a class="graphic graphic_diagnosticimage graphicRef122934" href="/z/d/graphic/122934.html" rel="external">image 1</a>).  </p><p class="headingAnchor" id="H60229745"><span class="h1">DISEASE-SPECIFIC SCORING SYSTEMS</span><span class="headingEndMark"> — </span>Disease-specific scoring systems are also available, including scoring systems for nonalcoholic fatty liver disease (NAFLD), alcoholic hepatitis, primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC). However, it is not uncommon to encounter two or more concurrent diseases in a liver biopsy specimen, and no scoring systems are available that specifically address these situations.</p><p class="headingAnchor" id="H2349826112"><span class="h2">Nonalcoholic fatty liver disease</span><span class="headingEndMark"> — </span>NAFLD is subdivided into nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) although these are considered to be part of a spectrum. In NAFL, hepatic steatosis is present without evidence of hepatocyte ballooning degeneration or significant inflammation, whereas in NASH, hepatic steatosis is associated with hepatocyte ballooning degeneration and hepatic inflammation that may be histologically indistinguishable from alcohol-associated steatohepatitis [<a href="#rid24">24,25</a>]. The clinical features and diagnosis of NAFLD are discussed separately (See  <a class="medical medical_review" href="/z/d/html/3625.html" rel="external">"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults"</a>.)</p><p>Although liver biopsy can confirm the diagnosis of NASH, grade disease severity, and accurately stage fibrosis, noninvasive methods for evaluating NASH are being studied. </p><p class="headingAnchor" id="H1361326123"><span class="h3">Brunt scheme for NASH</span><span class="headingEndMark"> — </span>The Brunt scheme includes grading and staging histologic features of NASH. This system is easily reproducible and continues to be used in most medical centers in the United States. Grade, which ranges from mild, moderate, to severe (corresponding to grades 1,2,3) is based on the combined features of steatosis, ballooning, and lobular and portal inflammation. Stage refers to the degree of fibrosis. The stage of fibrosis also takes into consideration the location of fibrosis, particularly in the early stage of disease [<a href="#rid26">26</a>]: Stage 1, zone 3 perisinusoidal fibrosis; Stage 2, both zone 3 perisinusoidal fibrosis and portal fibrosis; Stage 3, bridging fibrosis; and Stage 4, cirrhosis.</p><p class="headingAnchor" id="H2031372065"><span class="h3">Nonalcohol-associated fatty liver activity score</span><span class="headingEndMark"> — </span>The nonalcohol-associated fatty liver activity score (NAS) (<a class="graphic graphic_picture graphicRef97419 graphicRef97420 graphicRef97421" href="/z/d/graphic/97419.html" rel="external">picture 10A-C</a> and <a class="graphic graphic_table graphicRef98135" href="/z/d/graphic/98135.html" rel="external">table 8</a>) is a histologic evaluation system that includes the full spectrum of nonalcohol-associated fatty liver disease histologic changes and can assess changes following therapy in both adult and pediatric patients [<a href="#rid24">24</a>]. The NAS is the unweighted sum of scores for:</p><p class="bulletIndent1"><span class="glyph">●</span>Steatosis </p><p class="bulletIndent1"><span class="glyph">●</span>Lobular inflammation </p><p class="bulletIndent1"><span class="glyph">●</span>Ballooning </p><p></p><p>The NAS ranges from 0 to 8 [<a href="#rid24">24</a>]. Fibrosis is not included in the NAS. In the study that derived the NAS, scores of 0 to 2 occurred in cases largely considered not diagnostic of NASH; scores of 3 to 4 were evenly divided among those considered not diagnostic, borderline, or positive for NASH; and scores of 5 to 8 occurred in cases that were largely considered diagnostic of NASH [<a href="#rid24">24</a>]. In practice, the NAS is used to grade the activity of NASH, rather than to make a histologic diagnosis of NASH [<a href="#rid27">27</a>]. The original role for the NAS was to assess liver biopsies for patients who were enrolling in clinical trials. However, threshold values for NAS do not always correlate with the diagnosis of NASH and therefore may not be used solely for establishing diagnosis.</p><p class="headingAnchor" id="H47275257"><span class="h3">Steatosis, activity and fibrosis system</span><span class="headingEndMark"> — </span>With the steatosis, activity, and fibrosis (SAF) system, a diagnosis of NASH can be established [<a href="#rid28">28</a>]. Steatosis, activity, and fibrosis are separately assessed and the sum of the scores for lobular inflammation and ballooning define activity (range, 0 to 4). Patients with activity score of 2 or greater are diagnosed with NASH.</p><p class="headingAnchor" id="H497091710"><span class="h3">Fatty liver inhibition and progression</span><span class="headingEndMark"> — </span>The fatty liver inhibition of progression (FLIP) pathology consortium created a histologic algorithm (FLIP algorithm) based on the SAF scoring system to limit interobserver variation among pathologists. [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H1366946536"><span class="h2">Alcoholic liver disease and alcoholic hepatitis</span><span class="headingEndMark"> — </span>Histologic grading and staging systems for alcoholic liver disease have not been validated, and scoring systems developed for NAFLD and NASH are being used for alcohol-related liver disease. Histologically, alcoholic steatohepatitis (ASH) is similar to NASH, and often these two entities are indistinguishable from each other on biopsy. Some features may favor a diagnosis of alcoholic hepatitis, though they are not specific to alcoholic hepatitis. These features include cholestasis, numerous well-formed Mallory-Denk bodies, neutrophilic satellitosis, and central hyaline sclerosis [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/15756.html" rel="external">"Interpretation of nontargeted liver biopsy findings in adults", section on 'Diseases associated with fatty liver'</a>.)</p><p>One study proposed a semiquantitative histologic scoring system (the Alcoholic Hepatitis Histologic Score [AHHS]) that relates to the prognosis in patients with alcoholic hepatitis (<a class="graphic graphic_table graphicRef98136" href="/z/d/graphic/98136.html" rel="external">table 9</a>) [<a href="#rid31">31</a>]. Based on multivariate regression analysis, the group came up with a scoring system that utilizes four histologic features, scoring each feature individually (degree of fibrosis, degree of neutrophil infiltration, type of bilirubinostasis, and presence of megamitochondria) (<a class="graphic graphic_picture graphicRef97422 graphicRef97423 graphicRef97454 graphicRef97455" href="/z/d/graphic/97422.html" rel="external">picture 11A-D</a>). The risk of death is positively associated with the stage of fibrosis and degree of bilirubinostasis and is negatively correlated with neutrophil infiltration and the presence of megamitochondria (ie, mild neutrophil infiltration or the absence of megamitochondria is associated with a worse prognosis). The individual scores are combined to reach a final score (maximum score of 9). The investigators found that a low score (0 to 3) was associated with a 90-day mortality of 3 percent, whereas moderate (4 to 5 points) and high (6 to 9 points) scores were associated with higher mortality rates (19 and 51 percent, respectively). However, a subsequent validation study showed only a fair level of agreement in assigning the different categories, and this may limit the use of AHHS in clinical practice [<a href="#rid32">32</a>].</p><p>The SALVE Grading and Staging System was developed and validated by a group of expert liver pathologists under the auspices of the European Association for the Study of the Liver [<a href="#rid33">33</a>]. Grade is based on the degree of steatosis, activity, and cholestasis. Alcohol-associated steatohepatitis requires both ballooning of hepatocytes and neutrophils in the lobule. The stage, which is adapted from the NASH Clinical Research Network staging for NAFLD and the Laennec system, refers to the degree of fibrosis and the subtypes of cirrhosis, respectively. There are seven possible fibrosis stages in this scheme. Both the grade and the stage in this system provide prognostic value.</p><p class="headingAnchor" id="H143941062"><span class="h2">Primary biliary cholangitis</span><span class="headingEndMark"> — </span>Primary biliary cholangitis (PBC) is classically staged using either the Scheuer system for PBC (<a class="graphic graphic_table graphicRef98137" href="/z/d/graphic/98137.html" rel="external">table 10</a> and <a class="graphic graphic_picture graphicRef97457 graphicRef97458 graphicRef97459 graphicRef97460" href="/z/d/graphic/97457.html" rel="external">picture 12A-D</a>) or a system proposed by Ludwig (<a class="graphic graphic_table graphicRef98138" href="/z/d/graphic/98138.html" rel="external">table 11</a>) that differs from the Batts-Ludwig system described above [<a href="#rid34">34-36</a>]. (See  <a class="medical medical_review" href="/z/d/html/3621.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of primary biliary cholangitis", section on 'Liver biopsy'</a>.)</p><p>Because these scoring systems do not include the degree of portal lymphoplasmacytic inflammation that may be found in association with PBC, a histologic staging and grading system specifically for PBC has been proposed. In the Nakanuma system, histologic stage is based on three features: fibrosis, bile duct loss, and deposition of copper-associated protein on orcein stain.</p><p>The final Nakanuma stage is obtained from the total score of the three features of histologic stage [<a href="#rid37">37,38</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Stage I = no or minimal progression (score of 0)</p><p class="bulletIndent1"><span class="glyph">●</span>Stage II = mild progression (score of 1 to 3)</p><p class="bulletIndent1"><span class="glyph">●</span>Stage III = moderate progression (score of 4 to 6)</p><p class="bulletIndent1"><span class="glyph">●</span>Stage IV = advanced progression (score of 7 to 9)</p><p></p><p>The Nakanuma scoring system for histologic grade includes degree of cholangitis activity (score 0 to 3), and hepatitis activity (score 0 to 3) [<a href="#rid37">37</a>]. A validation study using this system showed that the cholangitis and hepatitis activity scores did not correlate well with each other in terms of the degree of inflammation, while the staging system correlated with the patient outcome [<a href="#rid39">39</a>]. Another study demonstrated that this staging system correlated with laboratory values, progression of the disease, and the development of cirrhosis [<a href="#rid40">40</a>]. </p><p class="headingAnchor" id="H1929080470"><span class="h2">Primary sclerosing cholangitis</span><span class="headingEndMark"> — </span>It is uncommon to perform a liver biopsy to make a diagnosis of PSC, but if a biopsy is performed, the Ludwig histologic staging system used for PSC is as follows [<a href="#rid41">41-44</a>] (<a class="graphic graphic_picture graphicRef97461 graphicRef97462 graphicRef97486 graphicRef97487" href="/z/d/graphic/97461.html" rel="external">picture 13A-D</a> and <a class="graphic graphic_table graphicRef98139" href="/z/d/graphic/98139.html" rel="external">table 12</a>) (see  <a class="medical medical_review" href="/z/d/html/660.html" rel="external">"Primary sclerosing cholangitis in adults: Clinical manifestations and diagnosis", section on 'Liver biopsy'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Stage 1: The portal tracts are expanded by edema and fibrosis, and there is a mononuclear cell infiltration with some interface hepatitis and damage to isolated bile ducts. Proliferation of bile ductules with mononuclear and polymorphonuclear cells may also be present, although the inflammation is usually less dense than in PBC.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stage 2: Expansion of portal triads with fibrosis extending into the surrounding parenchyma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stage 3: Bridging fibrosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stage 4: Cirrhosis.</p><p>In a study that evaluated three scoring systems (Ishak, Ludwig and Nakanuma) to determine the applicability and prognostic value of scores in a group of PSC patients, interobserver agreement was moderate to substantial in all three systems [<a href="#rid12">12,35,37,38</a>]. All three staging systems were also shown to be independent predictors of both liver transplantation and complications related to cirrhosis, but they found that the Nakanuma staging system (while initially intended for staging PBC) was independently associated with the endpoint of PSC-related death and liver transplantation (HR 2.14, 95% CI 1.22-3.77). </p><p class="headingAnchor" id="H60230201"><span class="h2">Autoimmune hepatitis</span><span class="headingEndMark"> — </span>The histologic grading systems for chronic hepatitis are also applied to autoimmune hepatitis (AIH) because, no formal histologic classification system specifically for AIH has been established. (See <a class="local">'Chronic hepatitis'</a> above.)</p><p>For the last decade, a diagnostic scoring system developed by the International Autoimmune Hepatitis Group (IAIHG) has used simplified criteria that are based upon titers of autoantibodies, immunoglobulin levels, liver histology, and the exclusion of viral hepatitis [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/z/d/html/3665.html" rel="external">"Overview of autoimmune hepatitis", section on 'Diagnostic scoring systems'</a>.) </p><p>The simplified criteria have two categories: "definite autoimmune hepatitis" (score of 7 or more) or "probable autoimmune hepatitis" (score of 6 or less). On biopsy, 2 points are given to the typical AIH features of interface hepatitis with lymphocytic or lymphoplasmacytic infiltrate, rosettes, and emperipolesis. If one of these features is absent, only 1 point (compatible) is given. Although the simplified criteria have a high specificity for the diagnosis of AIH, their sensitivity is quite low. Histologic underscoring may be a reason for the low sensitivity of the simplified criteria. Furthermore, rosettes are a nonspecific feature and may be seen in any type of regenerative condition while emperipolesis is very difficult to identify on routine histology. Thus, several investigators have attempted to improve the sensitivity of diagnosing AIH on liver biopsy.  </p><p>Modified histologic criteria for AIH have been proposed and have used the Ishak grading scheme to determine the degree of inflammation and the Batts-Ludwig scheme for the stage of fibrosis. (See <a class="local">'Ishak score (modified Knodell score)'</a> above and <a class="local">'Batts-Ludwig system (modified Scheuer system)'</a> above.)</p><p>In addition to the Ishak necro-inflammatory activity score, the extent of plasma cell infiltrates and copper and CK/7 staining were incorporated to result in a composite histology score (score 0, 1, and 2). These modified criteria have increased the number of diagnostic histologic AIH cases in the probable or definite category, whereas such cases would have previously been classified as non-AIH using the simplified criteria [<a href="#rid46">46</a>].  </p><p>Other groups have included additional features such as increased lymphocyte apoptotic body count in portal tracts. Adding such features has resulted in more patients with AIH who meet criteria for the "definite" category using the simplified AIH scoring system [<a href="#rid47">47</a>]. </p><p class="headingAnchor" id="H1595363446"><span class="h2">Congestive hepatopathy</span><span class="headingEndMark"> — </span>The congestive hepatic fibrosis score (CHFS) is a grading system for congestive hepatopathy, and it is a useful indicator of disease severity. In a study including 42 patients with congestive hepatopathy who had liver biopsies and cardiac testing (ie, echocardiography or right heart catheterization), histologic features of sinusoidal dilatation, centrilobular hepatocyte atrophy, centrilobular fibrosis, and portal fibrosis correlated with right atrial pressures. Higher CHFS scores also correlated with right atrial and right ventricular dilation [<a href="#rid48">48</a>]. In addition, a validation study showed that the CHFS correlated with clinical markers of congestive hepatopathy (eg, laboratory studies, cardiac imaging) [<a href="#rid49">49</a>] (<a class="graphic graphic_diagnosticimage graphicRef122934" href="/z/d/graphic/122934.html" rel="external">image 1</a>). However, limitations of liver biopsy include the heterogeneous distribution of fibrosis in patients with congestive hepatopathy [<a href="#rid50">50</a>]. Accurate staging of liver fibrosis helps to assess hepatic function in patients with congestive hepatopathy, and for some patients, it is an important part of the evaluation for heart transplantation. (See  <a class="medical medical_review" href="/z/d/html/3528.html" rel="external">"Heart transplantation in adults: Indications and contraindications"</a>.)</p><p>Chronic elevation of hepatic venous pressure secondary to right-sided heart failure can lead to liver fibrosis. The etiology and management of congestive hepatopathy is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3592.html" rel="external">"Congestive hepatopathy"</a>.) </p><p>A growing number of patients with congestive hepatopathy are those who had congenital single ventricle systems and underwent the Fontan procedure, and the risk of liver disease after the Fontan procedure is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/95232.html" rel="external">"Management of complications in patients with Fontan circulation", section on 'Liver disease'</a>.)</p><p class="headingAnchor" id="H23841634"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background</strong> – Histologic scoring systems for chronic liver disease are used to characterize and predict disease progression, to determine prognosis, to guide treatment strategies, and to provide standards in clinical trials. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Scoring systems for chronic hepatitis</strong> – Commonly used scoring systems for chronic hepatitis include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The Knodell score/histology activity index (<a class="graphic graphic_table graphicRef56831" href="/z/d/graphic/56831.html" rel="external">table 1</a>) (see <a class="local">'Knodell score/histology activity index'</a> above).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The METAVIR score (<a class="graphic graphic_table graphicRef98097" href="/z/d/graphic/98097.html" rel="external">table 2</a>) (see <a class="local">'METAVIR score'</a> above).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The Ishak score (modified Knodell score) (<a class="graphic graphic_table graphicRef98101" href="/z/d/graphic/98101.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef98099" href="/z/d/graphic/98099.html" rel="external">table 4</a>) (see <a class="local">'Ishak score (modified Knodell score)'</a> above).</p><p></p><p class="bulletIndent1">These scoring systems include descriptions of both necroinflammatory activity and the degree of fibrosis. An important difference among the scoring systems is in the staging of fibrosis. Scoring systems that include more stages for describing fibrosis are better able to document small changes in fibrosis over time. The Knodell score assigns patients to one of four stages, the METAVIR score to one of five, and the Ishak score to one of six.</p><p></p><p class="bulletIndent1">Other scoring systems include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The Scheuer system (<a class="graphic graphic_table graphicRef98102" href="/z/d/graphic/98102.html" rel="external">table 5</a>) (see <a class="local">'Scheuer system'</a> above).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The Batts-Ludwig system (<a class="graphic graphic_table graphicRef98103" href="/z/d/graphic/98103.html" rel="external">table 6</a>) (see <a class="local">'Batts-Ludwig system (modified Scheuer system)'</a> above).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Laennec staging system (<a class="graphic graphic_table graphicRef98104" href="/z/d/graphic/98104.html" rel="external">table 7</a>) (see <a class="local">'Laennec staging system'</a> above).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other disease-specific scoring systems</strong> – Scoring systems also exist for specific liver diseases, including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nonalcohol-associated fatty liver disease (<a class="graphic graphic_table graphicRef98135" href="/z/d/graphic/98135.html" rel="external">table 8</a> and <a class="graphic graphic_table graphicRef98105" href="/z/d/graphic/98105.html" rel="external">table 13</a>) (see <a class="local">'Nonalcoholic fatty liver disease'</a> above).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Alcoholic hepatitis (<a class="graphic graphic_table graphicRef98136" href="/z/d/graphic/98136.html" rel="external">table 9</a>) (see <a class="local">'Alcoholic liver disease and alcoholic hepatitis'</a> above).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Primary biliary cholangitis (<a class="graphic graphic_table graphicRef98137" href="/z/d/graphic/98137.html" rel="external">table 10</a> and <a class="graphic graphic_table graphicRef98138" href="/z/d/graphic/98138.html" rel="external">table 11</a>) (see <a class="local">'Primary biliary cholangitis'</a> above).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Primary sclerosing cholangitis (<a class="graphic graphic_table graphicRef98139" href="/z/d/graphic/98139.html" rel="external">table 12</a>) (see <a class="local">'Primary sclerosing cholangitis'</a> above).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Congestive hepatopathy (see <a class="local">'Congestive hepatopathy'</a> above).</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Boyd A, Cain O, Chauhan A, Webb GJ. Medical liver biopsy: background, indications, procedure and histopathology. Frontline Gastroenterol 2020; 11:40.</a></li><li><a class="nounderline abstract_t">Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39:239.</a></li><li><a class="nounderline abstract_t">Schiano TD, Azeem S, Bodian CA, et al. Importance of specimen size in accurate needle liver biopsy evaluation of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2005; 3:930.</a></li><li><a class="nounderline abstract_t">Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38:1449.</a></li><li><a class="nounderline abstract_t">Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014; 20:475.</a></li><li><a class="nounderline abstract_t">Rousselet MC, Michalak S, Dupré F, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005; 41:257.</a></li><li><a class="nounderline abstract_t">Soloway RD, Baggenstoss AH, Schoenfield LJ, Summerskill WH. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Am J Dig Dis 1971; 16:1082.</a></li><li><a class="nounderline abstract_t">Goldin RD, Goldin JG, Burt AD, et al. Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. J Hepatol 1996; 25:649.</a></li><li><a class="nounderline abstract_t">Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431.</a></li><li><a class="nounderline abstract_t">Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20:15.</a></li><li><a class="nounderline abstract_t">Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289.</a></li><li><a class="nounderline abstract_t">Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696.</a></li><li><a class="nounderline abstract_t">Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13:372.</a></li><li><a class="nounderline abstract_t">Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19:1409.</a></li><li><a class="nounderline abstract_t">Fiel MI. Pathology of chronic hepatitis B and chronic hepatitis C. Clin Liver Dis 2010; 14:555.</a></li><li><a class="nounderline abstract_t">De Groote J, Desmet VJ, Gedigk P, et al. A classification of chronic hepatitis. Lancet 1968; 2:626.</a></li><li><a class="nounderline abstract_t">Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992; 15:572.</a></li><li><a class="nounderline abstract_t">Sun Y, Zhou J, Wang L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment. Hepatology 2017; 65:1438.</a></li><li><a class="nounderline abstract_t">Kutami R, Girgrah N, Wanless I, et al. The Laennec grading system for assessment of hepatic fibrosis: validation by correlation with wedged hepatic vein pressure and clinical features. Hepatology 2000; 32:407A.</a></li><li><a class="nounderline abstract_t">Rastogi A, Maiwall R, Bihari C, et al. Cirrhosis histology and Laennec staging system correlate with high portal pressure. Histopathology 2013; 62:731.</a></li><li><a class="nounderline abstract_t">Kim SU, Oh HJ, Wanless IR, et al. The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis. J Hepatol 2012; 57:556.</a></li><li><a class="nounderline abstract_t">Dong KS, Liang BY, Zhang ZY, et al. Histologic severity of liver cirrhosis: A key factor affecting surgical outcomes of hepatocellular carcinoma in patients with portal hypertension. Asian J Surg 2019; 42:981.</a></li><li><a class="nounderline abstract_t">Theise ND, Jia J, Sun Y, et al. Progression and regression of fibrosis in viral hepatitis in the treatment era: the Beijing classification. Mod Pathol 2018; 31:1191.</a></li><li><a class="nounderline abstract_t">Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41:1313.</a></li><li><a class="nounderline abstract_t">Brunt EM, Kleiner DE, Carpenter DH, et al. NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology 2021; 73:2028.</a></li><li><a class="nounderline abstract_t">Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94:2467.</a></li><li><a class="nounderline abstract_t">Brunt EM, Kleiner DE, Wilson LA, et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011; 53:810.</a></li><li><a class="nounderline abstract_t">Bedossa P, Poitou C, Veyrie N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012; 56:1751.</a></li><li><a class="nounderline abstract_t">Bedossa P, FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 2014; 60:565.</a></li><li><a class="nounderline abstract_t">Elphick DA, Dube AK, McFarlane E, et al. Spectrum of liver histology in presumed decompensated alcoholic liver disease. Am J Gastroenterol 2007; 102:780.</a></li><li><a class="nounderline abstract_t">Altamirano J, Miquel R, Katoonizadeh A, et al. A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology 2014; 146:1231.</a></li><li><a class="nounderline abstract_t">Horvath B, Allende D, Xie H, et al. Interobserver Variability in Scoring Liver Biopsies with a Diagnosis of Alcoholic Hepatitis. Alcohol Clin Exp Res 2017; 41:1568.</a></li><li><a class="nounderline abstract_t">Lackner C, Stauber RE, Davies S, et al. Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease. J Hepatol 2021; 75:810.</a></li><li><a class="nounderline abstract_t">Scheuer P. Primary biliary cirrhosis. Proc R Soc Med 1967; 60:1257.</a></li><li><a class="nounderline abstract_t">Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978; 379:103.</a></li><li><a class="nounderline abstract_t">Scheuer PJ. Ludwig Symposium on biliary disorders--part II. Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis. Mayo Clin Proc 1998; 73:179.</a></li><li><a class="nounderline abstract_t">Nakanuma Y, Zen Y, Harada K, et al. Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: Interobserver agreement. Pathol Int 2010; 60:167.</a></li><li><a class="nounderline abstract_t">de Vries EM, de Krijger M, Färkkilä M, et al. Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study. Hepatology 2017; 65:907.</a></li><li><a class="nounderline abstract_t">Harada K, Hsu M, Ikeda H, et al. Application and validation of a new histologic staging and grading system for primary biliary cirrhosis. J Clin Gastroenterol 2013; 47:174.</a></li><li><a class="nounderline abstract_t">Kakuda Y, Harada K, Sawada-Kitamura S, et al. Evaluation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems. Hum Pathol 2013; 44:1107.</a></li><li><a class="nounderline abstract_t">Portmann B, Zen Y. Inflammatory disease of the bile ducts-cholangiopathies: liver biopsy challenge and clinicopathological correlation. Histopathology 2012; 60:236.</a></li><li><a class="nounderline abstract_t">Ludwig J. Surgical pathology of the syndrome of primary sclerosing cholangitis. Am J Surg Pathol 1989; 13 Suppl 1:43.</a></li><li><a class="nounderline abstract_t">Ludwig J, Barham SS, LaRusso NF, et al. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1981; 1:632.</a></li><li><a class="nounderline abstract_t">LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL. Current concepts. Primary sclerosing cholangitis. N Engl J Med 1984; 310:899.</a></li><li><a class="nounderline abstract_t">Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48:169.</a></li><li><a class="nounderline abstract_t">Balitzer D, Shafizadeh N, Peters MG, et al. Autoimmune hepatitis: review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria. Mod Pathol 2017; 30:773.</a></li><li><a class="nounderline abstract_t">Franceschini T, Vasuri F, Muratori P, et al. A practical histological approach to the diagnosis of autoimmune hepatitis: experience of an Italian tertiary referral center. Virchows Arch 2021; 479:937.</a></li><li><a class="nounderline abstract_t">Dai DF, Swanson PE, Krieger EV, et al. Congestive hepatic fibrosis score: a novel histologic assessment of clinical severity. Mod Pathol 2014; 27:1552.</a></li><li><a class="nounderline abstract_t">Bosch DE, Koro K, Richards E, et al. Validation of a Congestive Hepatic Fibrosis Scoring System. Am J Surg Pathol 2019; 43:766.</a></li><li><a class="nounderline abstract_t">Dhall D, Kim SA, Mc Phaul C, et al. Heterogeneity of Fibrosis in Liver Biopsies of Patients With Heart Failure Undergoing Heart Transplant Evaluation. Am J Surg Pathol 2018; 42:1617.</a></li></ol></div><div id="topicVersionRevision">Topic 3635 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31885839" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Medical liver biopsy: background, indications, procedure and histopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12873821" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16234033" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Importance of specimen size in accurate needle liver biopsy evaluation of patients with chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14647056" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Sampling variability of liver fibrosis in chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24574716" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15660389" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Sources of variability in histological scoring of chronic viral hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5135770" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8938541" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7308988" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8020885" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8690394" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7560864" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Histological grading and staging of chronic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1808228" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Classification of chronic viral hepatitis: a need for reassessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7503362" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Chronic hepatitis. An update on terminology and reporting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21055682" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pathology of chronic hepatitis B and chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4175170" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A classification of chronic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1551632" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28027574" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The Laennec grading system for assessment of hepatic fibrosis: validation by correlation with wedged hepatic vein pressure and clinical features</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23470026" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cirrhosis histology and Laennec staging system correlate with high portal pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22617153" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30782497" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Histologic severity of liver cirrhosis: A key factor affecting surgical outcomes of hepatocellular carcinoma in patients with portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29700417" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Progression and regression of fibrosis in viral hepatitis in the treatment era: the Beijing classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15915461" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Design and validation of a histological scoring system for nonalcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33111374" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : NAFLD: Reporting Histologic Findings in Clinical Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10484010" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21319198" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22707395" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24753132" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17222323" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Spectrum of liver histology in presumed decompensated alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24440674" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A histologic scoring system for prognosis of patients with alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28654190" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Interobserver Variability in Scoring Liver Biopsies with a Diagnosis of Alcoholic Hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34126105" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6066569" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/150690" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9473003" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Ludwig Symposium on biliary disorders--part II. Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20403042" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: Interobserver agreement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27880989" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23269312" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Application and validation of a new histologic staging and grading system for primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23313306" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Evaluation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21668470" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Inflammatory disease of the bile ducts-cholangiopathies: liver biopsy challenge and clinicopathological correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2699167" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Surgical pathology of the syndrome of primary sclerosing cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7308996" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6366557" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Current concepts. Primary sclerosing cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18537184" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Simplified criteria for the diagnosis of autoimmune hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28106105" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Autoimmune hepatitis: review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34189631" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A practical histological approach to the diagnosis of autoimmune hepatitis: experience of an Italian tertiary referral center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24925051" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Congestive hepatic fibrosis score: a novel histologic assessment of clinical severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30950843" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Validation of a Congestive Hepatic Fibrosis Scoring System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30273196" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Heterogeneity of Fibrosis in Liver Biopsies of Patients With Heart Failure Undergoing Heart Transplant Evaluation.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
